A Twelve-month Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of QL1206 in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture
Latest Information Update: 14 Feb 2023
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 01 Feb 2023 Status changed from recruiting to completed, according to Results published in the Acta Pharmacologica Sinica.
- 01 Feb 2023 Results published in the Acta Pharmacologica Sinica
- 05 Nov 2019 Planned number of patients changed from 216 to 440.